Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MELK | Q14680 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 4/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.48 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.45 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.45 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.45 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.45 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.45 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.45 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013707 | 0.89 | NPC1 (0.53) | NPC1RAB9AMAPTMELKSYK | |
| SCHEMBL3248558 | 0.89 | MELK (0.56) | NPC1RAB9AMAPTMELKSLC2A1 | |
| Hydrochloric Acid SCHEMBL3118453 | 0.88 | NPC1 (0.51) | NPC1RAB9AMAPTMELKSYK | |
| SCHEMBL29793289 | 0.86 | NPC1 (0.67) | NPC1RAB9AMAPTHSD17B1ALDH1A1 | |
| SCHEMBL21584068 | 0.86 | NPC1 (0.67) | NPC1RAB9AMAPTHSD17B1ALDH1A1 | |
| SCHEMBL3440731 | 0.83 | ALDH1A1 (0.69) | MAPTMELKSLC2A1HTR2CHTR2B | |
| SCHEMBL1466022 | 0.82 | NPC1 (0.67) | NPC1RAB9AMAPTHSD17B1ALDH1A1 | |
| SCHEMBL31048932 | 0.82 | NPC1 (0.67) | NPC1RAB9AMAPTHSD17B1ALDH1A1 | |
| SCHEMBL33121 | 0.82 | ALDH1A1 (0.68) | NPC1RAB9AMAPTHSD17B1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7560518 | 0.81 | ALDH1A1 (0.67) | MAPTMELKSLC2A1HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
| US-20090042862-A1 | NOVEL COMPOUNDS | BEST DESMOND JOHN | 2009-02-12 | — | — | US | disclosed |
| US-7446103-B2 | Bicyclic benzamide compound as histamine H3 receptor ligand useful in the treatment of neurological diseases | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| EP-1554243-B1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| EP-1554243-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | HRH3, HRH4, HRH1 | NPC1 2143/4885RAB9A 1241/4885MAPT 423/4885 |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | NPC1 1764/4885RAB9A 2688/4885MAPT 3598/4885 |
| US-20090042862-A1 | NOVEL COMPOUNDS | GRIN2C, GRIN2A, GRIN2B | NPC1 744/4885RAB9A 1174/4885MAPT 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.